This was predominantly a safety trial. The phase III efficacy data was already released. In terms of efficacy data from this trial, only 24% of patients had resolution of headache after two hours and 14% of patients discontinued the patch because of irritation at the application site.

Migraine is a crowded field. Sorry to hear about your migraines. Have you already tried the other ten or so approved therapies?